NEW YORK—BioAge Labs, a US-based biotechnology company specializing in anti-aging therapies, has announced the appointment of Jean-Pierre Garnier, the former chief executive officer of GlaxoSmithKline (GSK), as Chairman of its board of directors. Garnier’s extensive experience in the pharmaceutical industry is expected to provide strategic guidance as BioAge Labs advances its pipeline of innovative treatments.
Garnier’s tenure as CEO of GSK spanned from 2000 to 2008, a period that included significant acquisitions, such as the USD 720 million purchase of Sirtris Pharmaceuticals, which was later dissolved in 2023. Following his time at GSK, Garnier took the helm at Pierre Fabre for two years, further expanding his leadership in the biopharmaceutical sector. His career also includes board positions at notable biotech companies like Actelion, Cellectis, and Idorsia.
BioAge Labs, founded in 2015, recently secured a substantial investment of USD 170 million in a Series D financing round in February 2024. The funds are earmarked for the development of a next-generation oral weight loss drug. The drug candidate, BGE-105 (azelaprag), is an apelin receptor agonist licensed from Amgen and is being developed in combination with a GLP-1 product. In addition to weight loss, azelaprag is also being explored for its potential in treating diabetes and heart diseases, showcasing BioAge Labs’ commitment to addressing multiple health concerns with innovative pharmaceutical solutions. – Flcube.com
